HEPA — Hepion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Hepion Pharmaceuticals Appoints Dr Launa Aspeslet As Chief Operating Officer
Brief: Hepion Pharmaceuticals Announces Clinical Collaboration With HepQuant In Phase 2B NASH Trial
Brief: Hepion Pharmaceuticals Says Rencofilstat, In Combination With An Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity In A Nonclinical Liver Cancer Study
Brief: Hepion Pharmaceuticals Announces USAN Selection Of "Rencofilstat" As Nonproprietary Name For CRV431
U.S. STOCKS ON THE MOVE-BlackBerry, Boeing, Mastercard, Banks, COVID-19 vaccine stocks
U.S. STOCKS ON THE MOVE-Titan Pharma, Kellogg, Nordstrom, Embraer SA, Groupon
Hepion shares up as FDA clears co's lead candidate for mid-stage trial
Brief: Hepion Pharmaceuticals Announces FDA Clearance Of Ind Application For CRV431 In The Treatment Of Liver Cancer
Brief: Hepion Pharmaceuticals Receives FDA Fast Track Designation For CRV431 For The Treatment Of NASH
Brief: Hepion Pharmaceuticals And Fibrofind Announce Anti-Cancer Activity Of CRV431 In A Nonclinical Liver Cancer Study
Brief: All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431
Brief: Additional Data from Hepion Pharmaceuticals' Phase 2a Trial Further Strengthens CRV431 Clinical Profile
Brief: Hepion Pharmaceuticals Announces Positive Topline Data From Phase 2A ‘AMBITION’ Nash Trial
Brief: Hepion Pharmaceuticals Announces Adjournment Of Annual Meeting
Brief: Hepion Pharmaceuticals To Be Added To The Russell Microcap® Index
Hepion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Hepion Pharmaceuticals Completes Final Patient Recruitment In Phase 2A Trial Of CRV431
Brief: Hepion Pharmaceuticals Files For Mixed Shelf Of Up To $350 Million
Brief: Hepion Pharmaceuticals Announces Positive Results From Non-Alcoholic Fatty Liver Disease Trial